Gene Therapy for Ophthalmic Disorders | August 5-6 - EDT | Online

Conference themes
More companies than ever before are realizing the potential of gene therapies to treat a wide range of ophthalmic disorders but in practice there are still hurdles to overcome.

A variety of unique challenges must be addressed to effectively bring gene therapies to patients, from developing preclinical models that accurately translate to the clinic to validating clinical endpoints that will satisfy regulators.

Professional congress organizer (PCO)
Hanson Wade

Notes
Brochure: https://go.evvnt.com/645519-1?pid=4832

Speakers: Wiley Chambers, FDA, Thierry Bordet, Eyevensys, Dan Chung, Spark Therapeutics, Viral Kansara, Clearside Biomedical Inc., Brian Mansfield, Foundation for Fighting Blindness, and more.

https://go.evvnt.com/645519-2?pid=4832

Mr. Customer Service